Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 193

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 193
---
, foreign currency translation, bank charges
and interest expense, and interest income earned on our cash and cash equivalents and short-term deposits.

Results of Operations

For a discussion of our results
of operations for the year ended December 31, 2022, including a year-to-year comparison between 2023 and 2022, and a discussion of our
liquidity and capital resources for the year ended December 31, 2022, refer to Item 5. “ Operating and Financial Review and Prospects”
in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 7, 2024.

The following table summarizes
our results of operations for the years ended December 31, 2023 and 2024:

                                     Year Ended December 31,                                                                      
                                     2023                                     2024                  Change                        
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Operating expenses:                                                                                                             
  Research and development, net      $                            26,424      $         27,020      $             596        2.3  
  Marketing expenses                                               1,924                 2,349                    425       22.1  
  General and administrative                                       7,332                 6,673                   (659       (9.0  
  Total operating loss               $                            35,680      $         36,042      $             362        1.0  
  Loss from operations:                                                                                                           
  Financial (income), net                                         (6,539                (4,298                  2,241      (34.3  
  Loss before taxes on income                                     29,141                31,744                  2,603        8.9  
  Tax on income                                                       16                     6                    (10      (62.5  
  Net loss                           $                            29,157      $         31,750      $           2,593        8.9  

Comparison of the Year Ended December 31,
2023 and 2024

Research and development, net

Research and development,
net increased by $596 from $26,424 for the year ended December 31, 2023 to $27,020 for the year ended December 31, 2024. The increase
in research and development expense was primarily attributable to increased employee compensation and benefits, including share-based